Who is sponsoring NCT06875648?

NCT06875648 is sponsored by Hansung University.

What drugs are being tested in NCT06875648?

Interventions in NCT06875648: Not applicable (observational study).

What condition does NCT06875648 study?

NCT06875648 studies Colorectal Cancer; Gut Microbiota Dysbiosis.

Is NCT06875648 still recruiting?

NCT06875648 is currently completed. Last updated 18 March 2025.

Last reviewed 2025-03-18 · How we verify

NCT06875648

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intestinal Flora Differences Between Colorectal Cancer Patients and Healthy Individuals

Completed Last updated 18 March 2025

What this trial tests

trial testing Not applicable (observational study) in Colorectal Cancer; Gut Microbiota Dysbiosis in 61 participants. Completed in 1 March 2025.

Timeline

1 January 2021

Primary endpoint
1 March 2025

1 March 2025

Quick facts

Lead sponsor	Hansung University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	61
Start date	1 January 2021
Primary completion	1 March 2025
Estimated completion	1 March 2025
Sites	1 location across China

Drugs / interventions tested

Not applicable (observational study)

Conditions studied

Colorectal Cancer; Gut Microbiota Dysbiosis — all drugs for Colorectal Cancer; Gut Microbiota Dysbiosis →

Sponsor

Hansung University

Who can join

Adults 18 to 80, any sex, with Colorectal Cancer; Gut Microbiota Dysbiosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational case-control study aims to compare the composition of intestinal microbiota between colorectal cancer (CRC) patients and healthy individuals. Fecal samples from 36 CRC patients and 25 healthy controls were analyzed for bacterial abundance. Results indicate significant differences in beneficial, neutral, and harmful bacterial populations between groups, with CRC patients showing reduced beneficial flora (e.g., Lactobacillus) and increased harmful/neutral flora (e.g., Staphylococcus). Further stratification by cancer stage (I-III) revealed progressive dysbiosis with disease progression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Not applicable (observational study)

Trials testing the same drug.

NCT05097677 — Follow-up of Covid-19 Long Term Sequelae · completed

Other Hansung University trials

Trials by the same sponsor.

NCT06718062 — Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia · Phase 4 · completed
NCT06860503 — Thrombelastography for Coagulopathy in Chinese Snakebites · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06875648 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hansung University
Last refreshed: 18 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06875648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing